ArriVent BioPharma, Inc. (AVBP) vs Avalyn Pharma Inc. Common Stock (AVLN)

A side-by-side comparison of ArriVent BioPharma, Inc. and Avalyn Pharma Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
ArriVent BioPharma, Inc. logo
AVBP
ArriVent BioPharma, Inc.
$1.33B
$28.46HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Avalyn Pharma Inc. Common Stock logo
AVLN
Avalyn Pharma Inc. Common Stock
$1.17B
$26.36HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT

Total return — AVBP vs AVLN

growth of $100 · dividends reinvested · last 1y
AVBP -8.5% (-8.5%/yr)AVLN -8.3% (-8.3%/yr)AVLN compounded faster over this window
90100110120130Start $100$92$92
AVBP AVLN

AVBP vs AVLN: by the numbers

  • •AVBP is the larger company ($1.33B vs $1.17B market cap).

Metrics side by side

Valuation

MetricAVBPAVLN
P/B ratio3.612.93

Profitability

MetricAVBPAVLN
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-44.63%N/A
ROIC-47.96%-67.73%

Go deeper

Full AVBP analysisFull AVLN analysisInteractive comparison tool

Dig into the metrics

ArriVent BioPharma ROEAvalyn Pharma Inc. Common Stock ROEArriVent BioPharma operating marginAvalyn Pharma Inc. Common Stock operating marginArriVent BioPharma revenue growthAvalyn Pharma Inc. Common Stock revenue growthArriVent BioPharma free cash flowAvalyn Pharma Inc. Common Stock free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.